What is Quell Therapeutics?
Quell Therapeutics is a pioneering biotechnology firm focused on developing engineered T-regulatory (Treg) cell therapies. The company aims to leverage the inherent immune-suppressive properties of Tregs to address a range of serious medical conditions driven by the immune system. By harnessing and directing these cells, Quell Therapeutics seeks to create novel therapeutic solutions for autoimmune diseases, inflammatory conditions, and transplant rejection, marking a significant advancement in cell therapy.
How much funding has Quell Therapeutics raised?
Quell Therapeutics has raised a total of $196M across 2 funding rounds:
Series A
$40M
Series B
$156M
Series A (2021): $40M with participation from UCL Technology Fund and Syncona
Series B (2021): $156M led by Fidelity, SV Health Investors, Point72 Ventures, Ridgeback Capital Investments, Syncona, Jeito, Monashee Investment Management, British Patient Capital, Janus Henderson Investors, and Tekla Healthcare Opportunities
Key Investors in Quell Therapeutics
Fidelity
Fidelity Investments is an international provider of financial services and investment resources that help individuals and institutions meet their financial objectives.
SV Health Investors
SV Health Investors is a specialist investment firm backing innovative health care and life science companies, partnering with founders and management to provide capital, sector expertise and active support from early growth through scale and value creation.
Syncona
Syncona is a FTSE250 company dedicated to founding, building, and funding healthcare companies that aim to provide transformative treatments for patients facing significant unmet medical needs. The company manages a diversified portfolio of life science firms, including those in various clinical stages, from pre-clinical to late-stage development.
What's next for Quell Therapeutics?
With a substantial enterprise-level funding injection, Quell Therapeutics is poised to accelerate its research and development pipeline. The company's strategic focus will likely involve advancing its Treg cell therapy candidates through clinical trials, expanding its manufacturing capabilities, and forging key partnerships within the healthcare ecosystem. This significant backing from prominent investors suggests confidence in Quell's therapeutic approach and its potential to address unmet medical needs, paving the way for future commercialization and market leadership.
See full Quell Therapeutics company page
